The vascular endothelium and human diseases

International Journal of Biological Sciences

Volumn 9, Issue 10, 2013, Pages 1057-1069

  Rajendran, Peramaiyan ^a   Rengarajan, Thamaraiselvan ^a   Thangavel, Jayakumar ^b   Nishigaki, Yutaka ^a   Sakthisekaran, Dhanapal ^c   Sethi, Gautam ^d   Nishigaki, Ikuo ^a  

^a NPO International Laboratory of Biochemistry   (Japan)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF MADRAS   (India)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Atherosclerosis; Cancer; Endothelial dysfunction; Endothelium; Stroke

Indexed keywords

ATHEROSCLEROSIS; CANCER.; CEREBROVASCULAR ACCIDENT; DISEASES; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; VASCULAR ENDOTHELIUM;

ATHEROSCLEROSIS; CANCER.; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; STROKE;

DISEASE; ENDOTHELIUM, VASCULAR; HUMANS;

EID: 84892914260     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7502     Document Type: Review

References (121)

1. Wilson SH and Lerman A. Function of Vascular Endothelium. Heart Physiology and Pathophysiology 2001;:27.
2. Durand MJ, Gutterman DD. Diversity in Mechanisms of Endothelium-Dependent Vasodilation in Health and Disease. Microcirculation 2013; 20(3):239-247.
3. Douglas B Cines, Eleanor S Pollak, Clayton A Buck, et al. Endothelial Cells in Physiology and in the Pathophysiology of Vascular Disorders. The Journal of The American Society of Hematology Blood 1998; 91(10): 3527-3561.
4. Patel JC. Functions of endothelium. Indian Journal of Medical Sciences 2001; 55:165-6.
5. Verhamme P, Hoylaerts MF. The pivotal role of the endothelium in haemostasis and thrombosis. Acta clinica Belgica 2006; 61(5): 213-9.
6. Stern DM, et al. Endothelium and Regulation of Coagulation. Diabetes care 1991 Feb;14(2):160-6.
7. Atherton A, Born GV. Quantitative investigations of the adhesiveness of circulating polymorphonuclear leucocytes to blood vessel walls. Journal of Physiology 1972; 222: 447-74.
8. Cerletti C, Evangelista V, de Gaetano G. P-selectin-β2 integrin cross-talk: a molecular mechanism for polymorphonuclear leukocyte recruitment at the site of vascular damage. The Journal of Thrombosis and Haemostasis 1999; 82:787-93.
9. De Gaetano G, Donati MB, Cerletti C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Pharmacolology Science 2003;24:245-52.
10. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111: 5271-81.
11. Smyth SS, McEver RP, Weyrich AS, et al. Platelet Colloquium Participants. Platelet functions beyond hemostasis. The Journal of Thrombosis and Haemostasis 2009;7: 1759-66.
12. Wagner R. Erlauterungstalfeln zur Physiologie and Entwicklungsgeschichte. Leipzig, Germany:Leopold Voss. 1839
13. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010;327: 580-3.
14. Hara T, Shimizu K, Ogawa F, et al. Platelets control leukocyte recruitment in a murine model of cutaneous arthus reaction. American Journal of Pathology 2010; 176: 259-69.
15. Barton M, Baretella O, Meyer MR. Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction. Br J Pharmacol. 2012; 165(3):591-602.
16. Michiels C. Endothelial Cell Functions. Journal of Cellular Physiology 2003; 196:430-443.
17. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor(s). American Journal of Physiology 1986; 250:H822-H827.
18. Devaraj S, Singh U, Jialal I. The Evolving Role of C-Reactive Protein in Atherothrombosis. Clinical Chemistry 2009; 55: 229-238.
19. Paulo Roberto BE, et al. Endothelium dysfunction classification: Why is it still an open discussion? International Journal of Cardiology 2009; 137(2):175-176.
20. Hadi AR Hadi, Cornelia S Carr, Jassim Al Suwaidi. Endothelial Dysfunction: Cardiovascular Risk Factors, Therapy, and Outcome. Vascular Health Risk Management 2005; 1(3): 183-198.
21. Vita JA, Hamburg NM. Does endothelial dysfunction contribute to the clinical status of patients with peripheral arterial disease? Canadian Journal of Cardiology 2010; 26(A):45A-50A.
22. Gordon MB, Jain R, Beckman JA, et al. The contribution of nitric oxide to exercise hyperemia in the human forearm. Vascular Medicine 2002; 7:163-8.
23. Gokce N, Keaney JF, Menzoian JO, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function. Circulation 2002;105:1567-72.
24. Widlansky ME, Gokce N, Keaney JF, et al. The clinical implications of endothelial dysfunction. Journal of the American College of Cardiology 2003; 42:1149-60.
25. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. New England Journal of Medicine 1987;316: 1371-5.
26. Kawashima S, Yamashita T, Ozaki M, et al. Endothelial NO synthase overexpression inhibits lesion formation in mouse model of vascular remodeling. Arteriosclerosis Thrombosis and Vascular Biology 2001;21: 201-7.
27. Vita JA, Holbrook M, Palmisano J, et al. Flow-induced arterial remodeling relates to endothelial function in the human forearm. Circulation 2008; 117:3126-33.
28. McGuigan MR, Bronks R, Newton RU, et al. Muscle fiber characteristics in patients with peripheral arterial disease. Medicine & Science in Sports & Exercise 2001;33: 2016-21.
29. Porcu P, Emanueli C, Kapatsoris M, et al. Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia. Circulation 2002;105: 67-72.
30. Tsui JC, Baker DM, Biecker E, et al. Potential role of endothelin 1 in ischaemia-induced angiogenesis in critical leg ischaemia. British Journal of Surgery 2002; 89: 741-7.
31. Yu J, deMuinck ED, Zhuang Z, et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proceedings of the National Academy of Sciences 2005; 102: 10999-1004.
32. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circulation Research 2002; 90: 1243-50.
33. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72.
34. Faxon DP, Fuster V, Libby P, et al. Atherosclerotic Vascular Disease Conference: Writing Group III: Pathophysiology. Circulation 2004;109:2617-25.
35. Huang AL, Silver AE, Shvenke E, et al. Predictive value of reactive hyperemia for cardiovascular events in patients with peripheral arterial disease undergoing vascular surgery. Arteriosclerosis, Thrombosis, and Vascular Biology 2007; 27:2113-9.
36. Gokce N, Keaney JF, Hunter LM, et al. Predictive value of noninvasivelydetermined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. Journal of American College of Cardiology 2003;:1769-75.
37. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: Evidence that subclinical rupture has a role in plaque progression. Circulation 2001;103: 934-40.
38. Makin A, Silverman SH, Lip GY. Peripheral vascular disease and Virchow's triad for thrombogenesis. QJM 2002; 95: 199-210.
39. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: Angiogenesis as a source of intraplaque hemorrhage. Arteriosclerosis, Thrombosis, and Vascular Biology 2005;25:2054-61.
40. Fronek A, DiTomasso DG, Allison M. Noninvasive assessment of endothelial activity in patients with peripheral arterial disease and cardiovascular risk factors. Endothelium 2007; 14: 199-205.
41. Komai H, Higami Y, Tanaka H, et al. Impaired flow-mediated endothelium-dependent and endothelium-independent vasodilation of the brachial artery in patients with atherosclerotic peripheral vascular disease. Angiology 2008; 59: 52-6.
42. Poredos P, Golob M, Jensterle M. Interrelationship between peripheral arterial occlusive disease, carotid atherosclerosis and flow mediated dilation of the brachial artery. International Angiology 2003; 22:83-7.
43. Brevetti G, Silvestro A, Di Giacomo S, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. Journal of vascular surgery 2003; 8:374-9.
44. Kull I. J, Greene MT, Boerwinkle E, et al. Association of polymorphisms in NOS3 with the ankle-brachial index in hypertensive adults. Atherosclerosis 2008; 196:905-12.
45. Silvestro A, Scopacasa F, Ruocco A, et al. Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vascular Medicine 2003; 8: 225-32.
46. Tsui JC, Baker DM, Biecker E, et al. Evidence for the involvement of endothelin-1 but not urotensin-II in chronic lower limb ischaemia in man. European Journal of Vascular and Endovascular Surgery 2003;25:443-50.
47. Chang CC, Chen CJ. Secular trend of mortality from cerebral infarction and cerebral hemorrhage in Taiwan, 1974-1988. Stroke 1993;24:212-18.
48. Diaz JF, Hachinski VC, Pederson LL, Donald A. Aggregation of multiple risk factors for stroke in siblings of patients with brain infarction and transient ischemic attacks. Stroke 1986;17:1239-42.
49. Michael A. Moskowitz, Eng H. Lo, Costantino Iadecol. The Science of Stroke: Mechanisms in Search of Treatments. Neuron Review 2010; 67: 181-198.
50. Cosentino F, Sill JC, Katusic ZS. Endothelial L-arginine pathway and relaxations to vasopressin in canine basilar artery. American Journal of Physiology 1993; 33: H413-18.
51. Cosentino F, Rubattu S, Savoia C, et al. Endothelial Dysfunction and Stroke. Journal of Cardiovascular Pharmacology 2001; 38 (2):S75-S78.
52. Schiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-1659.
53. Park JB, Charbonneau F, Schiffrin EL. Correlation of endothelial function in large and small arteries in human essential hypertension. Journal of Hypertenion 2001; 19: 415-420.
54. Moncada S and Vane JR. Prostacyclin (PGI2), the vascular wall and vasodilation. In: Mechanisms of Vasodilation, ed. by P.A. Vanhoutte and I. Leusen, pp 107-121. Karger, Basel, 1978.
55. Panza JA, Quyyumi AA, Callahan TS, et al. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. Journal of the American College of Cardiology 1993; 21: 1145-1151.
56. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. Journal of Hypertension 2002;20: 71-78.
57. Taddei S, Virdis A, Ghiadoni L, et al. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97: 2222-2229.
58. Taddei S, Virdis A, Mattei P, et al. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94: 1298-1303.
59. Chen X, Touyz RM, Park JB et al. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 2001;38:606-611.
60. Touyz RM, Chen X, Tabet F, et al. Expression of a functionally active gp91phoxcontaining neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circulation Research 2002; 90: 1205-1213.
61. Lockette W, Otsuka Y, Carretero O. The loss of endotheliumdependent vascular relaxation in hypertension. Hypertension 1986; 8: II61-II66.
62. Yoshibayashi M, Nishioka M, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 1991; 84: 2280-2285.
63. Channick RN, Sitbon O, Barst RJ, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. Journal of American College of Cardiology 2004;43: 62S-67S.
64. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109: II27-II33.
65. Landmesser U, Harrison DG. Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation 2001; 104: 2638-2640.
66. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. Journal of Clinical Investigation 2003; 111: 1201-1209.
67. White CR, Darley-Usmar V, Berrington WR, et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proceedings of the National Academy of Sciences 1996;93:8745-8749.
68. Maier W, Cosentino F, Lutolf RB, et al. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. Journal of Cardiovascular Pharmacology 2000; 35: 173-178.
69. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
70. Eizawa Z, Yui Y, Inoue R, et al. Lysophosphatidylcholine inhibits endothelium-dependent hyperpolarization and N omega-nitro-l-arginine/indomethacinresistant endothelium-dependent relaxation in the porcine coronary artery. Circulation 1995;92: 3520-3526.
71. Chan H, Lougheed M, Laher I, et al. Oxidized low-density lipoprotein inhibits endothelium-dependent vasodilation by an antioxidant-sensitive, lysophosphatidylcholine-independent mechanism. Journal of Cardiovascular Pharmacology 2003; 41: 856-865.
72. Galley HF, Webster NR. Physiology of the endothelium. British Journal of Anaesthesia 2004; 93: 105-113.
73. Cunningham ME, Huribal M, Bala RJ, et al. Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Critical Care Medicine 1997; 25: 958-964.
74. Best PJ, Lerman A. Endothelin in cardiovascular disease: from atherosclerosis to heart failure. Journal of Cardiovascular Pharmacology 2000; 35: S61-S63.
75. Halim A, Kanayama N, Maradny E, Maehara K, et al. Endothelin-1 evoked an increase and oscillations in cytosolic calcium concentration in adherent single human platelets and increased GMP-140 (P-selectin) in platelet suspension. Thrombosis Research 1995; 80: 105-112.
76. Behrendt, Ganz P. Endothelial function. From vascular biology to clinical applications. American Journal of Cardiology 2002; 90: 40L-48L.
77. Daniele Versari, Elena Daghini, Agostino Virdis, et al. Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease. Diabetes Care 2009; 32 (2):314-321.
78. Mohanty P, Ghanim H, Hamouda W, et al. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. American Journal of Clinical Nutrition 2002;75:767-772.
79. Mohanty P, Hamouda W, Garg R, et al. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. Journal of Clinicla Endocrinology Metabolism 2000;85: 2970-2973.
80. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. The American Journal of Cardiology 1997; 79: 350-354.
81. Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52: 2882-2887.
82. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocrinology Review 2001; 22:36-52.
83. Baron AD, Brechtel G. Insulin differentially regulates systemic and skeletal muscle vascular resistance. American Journal of Physiology 1993; 265: E61-E67.
84. Clerk LH, Vincent MA, Lindner JR, et al. The vasodilatory actions of insulin on resistance and terminal arterioles and their impact on muscle glucose uptake. Diabetes Metabolism Resesach and Reviews 2004; 20: 3-12.
85. Muniyappa R, Iantorno M, Quon M.J. An integrated view of insulin resistance and endothelial dysfunction. Endocrinology and Metabolism Clinics of North America 2008; 37: 685-711.
86. Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism 2000; 49:147-150.
87. Mather K, Laakso M, Edelman S, et al. Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow. American Journal Physiology Endocrinology Metabolism 2000; 279: E1264-E1270.
88. Taddei S, Virdis A, Mattei P, et al. Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension. Circulation 1995; 92: 2911-2918.
89. Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001; 103: 1410-1415.
90. Xu J, Zou MH. Molecular Insights and Therapeutic Targets for Diabetic Endothelial Dysfunction. Circulation 2009; 120:1266-1286.
91. Zhu D, et al. Luteolin inhibits inflammatory response and improves insulin sensitivity in the endothelium. Biochimie 2011; 93: 506-512.
92. Li R, et al. Vascular resistance in prehypertensive rats: Role of PI3-kinase/Akt/eNOS signaling. European Journal of Pharmacology 2010;628(1-3): 140-147.
93. Yang Z, Li JC. Stimulation of endothelin-1 gene expression by insulin via phosphoinositide-3 kinase-glycogen synthase kinase-3β signaling in endothelial cells. Life Sciences 2008;82 (9-10): 512-518.
94. Barrett EJ, Wang H, Upchurch CT, et al. Insulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature. American Journal of Physiology Endocrinology Metabolism 2011;301(2): E252-63.
95. Barrett EJ, Eggleston EM, Inyard AC, et al. The vascular actions of insulin control its delivery to muscle and regulate the rate-limiting step in skeletal muscle insulin action. iabetologia 2009;52(5):752-64.
96. Genders AJ, Frison V, Abramson SR, et al. Endothelial cells actively concentrate insulin during its transendothelial transport. Microcirculation 2013; doi: 10.1111/micc.12044.
97. Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113:1888-1904.
98. Jonathan H Pinkney, Coen DA Stehouwer, Simon W Coppack, et al. Endothelial Dysfunction: Cause of the Insulin Resistance Syndrome. Diabetes 1997; 46 (2): 9-13.
99. Carmine Zoccali. The endothelium as a target in renal diseases. Journal of Nephrology 2007; 20 (12): S39-S44.
100. Keller G, Zimmer G, Mall G, et al. Nephron number in patients with primary hypertension. The New England Journal of Medicine 2003; 348: 101-8.
101. Jolanta Malyszko. Mechanism of endothelial dysfunction in chronic kidney disease. Clinical Chimica Acta 2010; 411: 1412-1420.
102. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. The Journal of Thrombosis and Haemostasis 1997;77: 408-23.
103. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. Journal of the American College of Cardiology 2005;46:518-23.
104. Raff U, Schwarz TK., Schmidt BM, et al. Renal resistive index-a valid tool to assess renal endothelial function in humans? Nephrology Dialysis Transplantation 2010; 25:1869-74.
105. Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obesity Review 2009;10:554-63.
106. Malyszko J, Malyszko JS, Kozminski P, et al. Adipokines, linking adipocytes and vascular function in hemodialyzed patients, may also be possibly related to CD146, a novel adhesion molecule. Clinical and Applied Thrombosis/Hemostasis 2008; 14: 338-45.
107. Stam F, Van GC, Becker A, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 2006; 17: 537-45.
108. Panichi V, Migliori M, De PS, Taccola D, Bianchi AM, Giovannini L, Norpoth M, Metelli MR, Cristofani R, Bertelli AA, Sbragia G, Tetta C, Palla R, Colombo R. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure. Nephron 2002; 91: 594-600.
109. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, Ball S, Townend JN, Baigent C. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43:244-53.
110. Stam F, van Guldener C, Schalkwijk CG, Ter Wee PM, Donker AJ, Stehouwer CD. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant 2003; 18: 892-8.
111. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68: 237-45.
112. Annuk M, Lind L, Linde T, Fellstrom B. Impaired endothelium-dependent vasodilatation in renal failure in humans. Nephrol Dial Transplant 2001; 16: 302-6.
113. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006; 47: 42-50.
114. Małyszko J, Małyszko JS, Myśliwiec M. Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis (CAPD). Kidney Blood Pressure Research 2004; 27: 71-7.
115. Disanza A, Steffen A, Hertzog M, et al. Actin polymerization machinery: the finish line of signaling networks, the starting point of cellular movement. Cell Molecular Life Science 2005;62:955-970.
116. Small JV, Resch GP. The comings and goings of actin: coupling protrusion and retraction in cell motility. Current Opinion in Cell Biology 2005;17: 517-523.
117. Small JV, Stradal T, Vignal E, et al. The lamellipodium: where motility begins. Trends in Cell Biology 2002; 12:112-120.
118. Atanu Basu, Umesh C. Chaturvedi. Vascular endothelium: the battle¢eld of dengue viruses. FEMS Immunol Med Microbiol 2008; 53:287-299.
119. Spiropoulou CF, Srikiatkhachorn A. The role of endothelial activation in dengue hemorrhagic fever and hantavirus pulmonary syndrome. Virulence. 2013 Aug 15;4(6):525-36.
120. Higashi Y, Yoshizumi M. Exercise and endothelial function: Role of endothelium-derived nitric oxide and oxidative stress in healthy subjects and hypertensive patients. Pharmacology & Therapeutics 2004;102: 87-96.
121. Balakumar P, et al. Pharmacological Interventions to Prevent Vascular Endothelial Dysfunction:Future Directions. Journal of health science 2008;54(1):1-16.